CombiMatrix Corp was originally incorporated in October 1995 as a California Corporation and later reincorporated as a Delaware Corporation in September 2000. It is a molecular diagnostics company that operates in the field of genetic analysis and molecular diagnostics through its wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc. (CMDX). CMDX operates as a diagnostics reference laboratory, providing DNA-based clinical diagnostic testing services to physicians, hospitals, clinics and other laboratories in the areas of pre-and postnatal development disorders and hematology/oncology genomics. The Company empowers physicians to positively impact patient care through the delivery of innovative molecular diagnostic services. It also owns a one-third minority interest in Leuchemix, Inc. (Leuchemix), a private drug development company focused on developing a series of compounds to address a number of oncology-related diseases. The Company's business competitors in the United States include other aCGH clinical laboratories, both commercial and academic, and include companies such as LabCorp (through its recent acquisition of Genzyme) Perkin-Elmer (through its recent acquisition of Signature Genomics) and approximately ten others. The Company's operations involve the use, transportation, storage and disposal of hazardous substances. As a result, it is subject to environmental and health and safety laws and regulations.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.